PMID- 23697945 OWN - NLM STAT- MEDLINE DCOM- 20150115 LR - 20220310 IS - 1520-5010 (Electronic) IS - 0893-228X (Print) IS - 0893-228X (Linking) VI - 26 IP - 7 DP - 2013 Jul 15 TI - Disruption of thioredoxin reductase 1 protects mice from acute acetaminophen-induced hepatotoxicity through enhanced NRF2 activity. PG - 1088-96 LID - 10.1021/tx4001013 [doi] AB - The critical importance of glutathione in mitigating the deleterious effects of electrophile generating drugs such as acetaminophen (APAP) is well established. However, the role of other antioxidant systems, such as that provided by thioredoxin, has not been extensively studied. Selenoprotein thioredoxin reductase 1 (Txnrd1) is important for attenuating activation of the apoptosis signaling-regulating kinase 1 (ASK1) and the c-Jun N-terminal kinase (JNK) pathway caused by high doses of APAP. Therefore, a detailed investigation of the role of Txnrd1 in APAP-induced hepatotoxicity was conducted. Liver-specific Txnrd1 knockout mice (Txnrd1(DeltaLiv)) were generated and treated with a hepatotoxic dose (400 mg/kg) of APAP for 1 or 6 h. Liver toxicity was assessed by measuring the activities of liver enzymes aspartate aminotransferase and alanine aminotransferase in serum, in addition to histopathological analysis of liver sections and analysis of glutathione levels. At 1 h post-APAP treatment, total and mitochondrial glutathione levels in control and Txnrd1(DeltaLiv) mice were similarly depleted. However, at 6 h post-APAP treatment, Txnrd1(DeltaLiv) mice were resistant to APAP toxicity as liver enzymes and histology were not significantly different from the corresponding untreated mice. Analyses revealed the compensatory up-regulation of many of the nuclear factor erythroid 2-related factor 2 (NRF2) target genes and proteins in Txnrd1(DeltaLiv) mice with and without APAP treatment. Yet, JNK was phosphorylated to a similar extent in APAP-treated control mice. The results suggest that Txnrd1(DeltaLiv) mice are primed for xenobiotic detoxication primarily through NRF2 activation. FAU - Patterson, Andrew D AU - Patterson AD AD - Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, Maryland 20892, United States. FAU - Carlson, Bradley A AU - Carlson BA FAU - Li, Fei AU - Li F FAU - Bonzo, Jessica A AU - Bonzo JA FAU - Yoo, Min-Hyuk AU - Yoo MH FAU - Krausz, Kristopher W AU - Krausz KW FAU - Conrad, Marcus AU - Conrad M FAU - Chen, Chi AU - Chen C FAU - Gonzalez, Frank J AU - Gonzalez FJ FAU - Hatfield, Dolph L AU - Hatfield DL LA - eng GR - Z01 BC005561-20/ImNIH/Intramural NIH HHS/United States GR - Z01 BC005561-21/ImNIH/Intramural NIH HHS/United States GR - Z01 BC005562-20/ImNIH/Intramural NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Intramural DEP - 20130607 PL - United States TA - Chem Res Toxicol JT - Chemical research in toxicology JID - 8807448 RN - 0 (NF-E2-Related Factor 2) RN - 0 (Nfe2l2 protein, mouse) RN - 362O9ITL9D (Acetaminophen) RN - EC 1.8.1.9 (Thioredoxin Reductase 1) RN - EC 1.8.1.9 (Txnrd1 protein, mouse) RN - GAN16C9B8O (Glutathione) SB - IM MH - Acetaminophen/*toxicity MH - Animals MH - Chemical and Drug Induced Liver Injury/*metabolism/pathology/*prevention & control MH - Glutathione/analysis MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Mice, Transgenic MH - NF-E2-Related Factor 2/genetics/*metabolism MH - Thioredoxin Reductase 1/*antagonists & inhibitors/deficiency/metabolism PMC - PMC6334300 MID - NIHMS1000650 COIS- The authors declare no competing financial interest. EDAT- 2013/05/24 06:00 MHDA- 2015/01/16 06:00 PMCR- 2019/01/16 CRDT- 2013/05/24 06:00 PHST- 2013/05/24 06:00 [entrez] PHST- 2013/05/24 06:00 [pubmed] PHST- 2015/01/16 06:00 [medline] PHST- 2019/01/16 00:00 [pmc-release] AID - 10.1021/tx4001013 [doi] PST - ppublish SO - Chem Res Toxicol. 2013 Jul 15;26(7):1088-96. doi: 10.1021/tx4001013. Epub 2013 Jun 7.